Project Grant K99CA315421
Award Date 8/13/26
Completion Date 7/31/28
Dollars Obligated $148K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $704,044 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms by which EZH2 inhibition enhances adoptive T-cell therapies for cancer. The research addresses resistance to CAR-T cell therapy, where only one-third of non-Hodgkin lymphoma patients receiving anti-CD19 CAR-T treatments achieve lasting remission. The project centers on the epigenetic modulator EZH2 and...
- The National Cancer Institute awarded the University of Pennsylvania $236,997 under the Cancer Biology Research program (CFDA 93.396) on August 19, 2026, for Project Grant R61CA309704. The award funds development of spatially engineered cellular neighborhood models to mimic malignant bone marrow niches from human biospecimens. The project will engineer hydrogel-microgel assemblies to control bone marrow cell pairing and create programmable cellular neighborhoods using core-shell microgel...
- The National Cancer Institute awarded the University of Pennsylvania $148,626 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) for a project investigating the role of N6-methyladenosine (m6A) modifications on mRNA during adaptive stress in prostate cancer. The funded work addresses drug resistance in prostate cancer by examining how the integrated stress response (ISR)—an adaptive cellular pathway triggered by cancer treatments and tumor microenvironment...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $135,637 on June 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into the molecular mechanisms of alternative lengthening of telomeres in cancer cells. The award funds investigation of how the Bloom syndrome helicase (BLM) protein initiates and regulates alternative lengthening of telomeres (ALT), a mechanism used by approximately 15 percent of cancers to maintain...
- The National Cancer Institute awarded Temple University $145,632 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training in cancer research careers. The project, titled "Understanding Eosinophilic Esophagitis-Mediated Inhibition of Esophageal Cancer," runs through August 31, 2027, with work performed in Philadelphia, Pennsylvania. The award funds training opportunities for individuals pursuing careers in basic, clinical, and...
- The National Cancer Institute awarded $457,683 to Beckman Research Institute of The City of Hope on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of ERBB signaling in ibrutinib-resistant mantle cell lymphoma (MCL). The research elucidates mechanisms by which MCL tumors evade BTK inhibition through ERBB-mediated survival pathways. The recipient will analyze gene expression patterns in ibrutinib-resistant MCL patient samples, develop isogenic...
- The National Cancer Institute awarded Yale University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and biomedical career development in cancer research. Yale will conduct basic research on the regulation of membrane-chromatin interactions during mitotic nuclear formation and their role in cancer cell survival. The project investigates how endoplasmic reticulum membranes and LEM-domain proteins, including LEMD2 and emerin,...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $126,220 on September 10, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research into mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma. The funded work investigates the intrinsic basis for early lymph node metastasis independent of tumor-derived preconditioning, with focus on the role of regulatory T cells (Tregs) in suppressing anti-tumor CD8 T cell cytotoxicity...
- The National Cancer Institute awarded the University of Pittsburgh $198,728 on January 16, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support doctoral research training in cancer biology. The award funds investigation into profilin-1 (PFN1) modulation of the tumor immune microenvironment in breast cancer, specifically examining whether genetic disruption of PFN1 increases CD8+ T cell infiltration and enhances the efficacy of immune checkpoint blockade immunotherapy. The...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded $831,988 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds a five-year project investigating the role of ASAH1-driven ceramide metabolism in Epstein Barr Virus-driven B-cell transformation under germinal center hypoxia. The research addresses...